ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Down 37.3% in July

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 57,200 shares, a decrease of 37.3% from the June 30th total of 91,300 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 55,300 shares, the days-to-cover ratio is currently 1.0 days.

ABIVAX Société Anonyme Stock Up 0.3 %

Shares of NASDAQ:ABVX opened at $11.86 on Friday. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.23. ABIVAX Société Anonyme has a 52-week low of $7.99 and a 52-week high of $17.02. The company has a fifty day moving average of $13.36 and a 200-day moving average of $13.60.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ABVX shares. BTIG Research began coverage on shares of ABIVAX Société Anonyme in a research report on Monday, May 20th. They issued a “buy” rating and a $43.00 target price for the company. Piper Sandler began coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They issued an “overweight” rating and a $42.00 target price on the stock. Guggenheim began coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Morgan Stanley upped their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 11th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, ABIVAX Société Anonyme currently has an average rating of “Moderate Buy” and a consensus price target of $34.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new stake in shares of ABIVAX Société Anonyme in the 1st quarter valued at $81,000. Capstone Investment Advisors LLC acquired a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $618,000. Ghisallo Capital Management LLC bought a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $642,000. Kennedy Capital Management LLC raised its stake in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares during the period. Finally, Rosalind Advisors Inc. bought a new position in ABIVAX Société Anonyme in the first quarter worth approximately $5,411,000. 47.91% of the stock is owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.